SEC FIlings Archives - Page 10 of 19

15 Nov

SEC FIlings

Initial statement of beneficial ownership of securities

December 14, 2022
Posted by Jitendra

15 Nov

SEC FIlings

Initial statement of changes in beneficial ownership of securities

December 14, 2022
Posted by Jitendra

15 Nov

SEC FIlings

Initial statement of beneficial ownership of securities

December 14, 2022
Posted by Jitendra

15 Nov

SEC FIlings

Initial statement of beneficial ownership of securities

December 14, 2022
Posted by Jitendra

14 Nov

SEC FIlings

Statement of acquisition of beneficial ownership by individuals – Amendment

November 17, 2022
Posted by Jitendra

10 Nov

SEC FIlings

Notification of removal from listing and/or registration

November 17, 2022
Posted by Jitendra

09 Nov

SEC FIlings

Current report

November 17, 2022
Posted by Jitendra

04 Nov

SEC FIlings

Quarterly report for quarter ending Sept 30, 2022

November 17, 2022
Posted by Jitendra

31 Oct

SEC FIlings

Prospectuses and communications, business combinations

November 17, 2022
Posted by Jitendra

31 Oct

SEC FIlings

Current report

November 17, 2022
Posted by Jitendra

SEC FIlings

Initial statement of beneficial ownership of securities

Initial statement of changes in beneficial ownership of securities

Initial statement of beneficial ownership of securities

Initial statement of beneficial ownership of securities

Statement of acquisition of beneficial ownership by individuals – Amendment

Notification of removal from listing and/or registration

Current report

Quarterly report for quarter ending Sept 30, 2022

Prospectuses and communications, business combinations

Current report

test according

Scilex Holding Company Chief Executive Officer and President Issues Letter to Stockholders Highlighting 2023 Accomplishments and Outlook for 2024

Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results For Gross And Net Sales For The Fiscal Year Ended December 31, 2023, Based On Currently Available Information

Scilex Holding Company Announces Filing of a New Drug Submission (NDS) to Health Canada’s Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for the Approval of ELYXYB® for Acute Treatment of Migraine With or Without

Scilex Holding Company Announces that According to Prescription Data from Symphony Health, ZTlido® is the Most Prescribed Non-Opioid Branded Pain Treatment By Pain Specialists